Volume 116, Issue 1 , Pages 65-72, July 2005
Modulation of GM-CSF release by enantiomers of β-agonists in human airway smooth muscle
Background
β2-Adrenergic receptor agonists can reduce the release of GM-CSF by human airway smooth muscle cells (HASMCs). These effects are considered anti-inflammatory and are ascribed to the activity of the (R)-enantiomer within the racemate of the agonist. However, the effect of the (S)-enantiomer on GM-CSF release, once thought to be inert, has not been extensively explored.
Objective
We hypothesized that the (S)-enantiomer may counter the effects of the (R)-enantiomer, potentially increasing GM-CSF release. Therefore, the effects of administration of individual and combined enantiomers on GM-CSF release were examined.
Methods
Cultured HASMCs were stimulated with IL-1β, TNF-α, and IFN-γ and treated with (R)-enantiomers and (S)-enantiomers of albuterol and formoterol, with and without propranolol and ICI-118,551, and in combination with dexamethasone. GM-CSF in the resulting conditioned media was assessed by ELISA.
Results
(R)-enantiomers significantly reduced GM-CSF release by as much as 41% (P < .05), which was reversible with propranolol. In contrast, (S)-enantiomers significantly increased GM-CSF release by as much as 34% (P < .05) over release with no drug, and by 25% to 40% (P < .05) when added with (R)-enantiomers. The decremental effect of dexamethasone was amplified by (R)-enantiomers but inhibited by (S)-enantiomers. Both propranolol and ICI-118,551 alone increased GM-CSF release in a concentration-dependent fashion, similar to (S)-enantiomers.
Conclusion
We conclude that GM-CSF release by HASMC is downregulated by (R)-enantiomers and enhanced by (S)-enantiomers. The reversal of (R)-enantiomer and dexamethasone effects by the (S)-enantiomer suggests suppression of their anti-inflammatory effects, perhaps through an antagonistic mechanism similar to propranolol.
Key words: Albuterol, β-receptors, cAMP, formoterol, inverse agonist, levalbuterol, propranolol, racemic
Abbreviations used: cAMP, Cyclic adenosine monophosphate, HASMC, Human airway smooth muscle cell
Supported by the American Respiratory Alliance of Western Pennsylvania and Sepracor, Inc.Disclosure of potential conflict of interest: Bill Ameredes and William Calhoun have consultant arrangements with Sepracor, Inc, receive grant/research support from Sepracor, Inc, and are on the speakers' bureau for Sepracor, Inc.
PII: S0091-6749(05)00526-9
doi:10.1016/j.jaci.2005.03.007
© 2005 American Academy of Allergy, Asthma and Immunology. Published by Elsevier Inc. All rights reserved.
Volume 116, Issue 1 , Pages 65-72, July 2005

